Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

NCT07342920 | Recruiting

• 1 other identifier: 9813
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis; Smoking, Vaping

Outcome Measures

Primary Outcomes (1)

• Prevalence of smoking in adults with cystic fibrosis

  The proportion of adults with cystic fibrosis who smoke: Example: If 10 out of 100 adults with cystic fibrosis smoke, then the prevalence of smoking in this group is 10%.

  Up to 12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient with confirmed cystic fibrosis

You may qualify if:

• Adult patient (≥ 18 years old)
• With confirmed cystic fibrosis
• Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

You may not qualify if:

• Patients who have undergone a double lung transplant for cystic fibrosis.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Pneumologie - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Cystic Fibrosis; Smoking; Vaping

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases; Behavior

Central Study Contacts

Romain Kessler, MD, PhD

CONTACT

33 3 69 55 03 77; Romain.Kessler@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 6, 2026
• First Posted: January 15, 2026
• Study Start: October 15, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 15, 2026
• Last Updated: January 15, 2026

Record last verified: 2026-01

Locations

FR (1)